Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol.
30 patients (10 normotensive, 20 hypertensive) with stable angina and positive treadmill exercise tests entered a double-blind, placebo-controlled crossover trial of metoprolol, 100 mg twice daily. At the end of each treatment phase, blood pressure was monitored for 24 h and Holter and real-time electrocardiographic (ECG) monitoring were carried out and an activity diary kept for 48 h. Blood samples for catecholamine measurement were taken after 30 min supine, 60 min standing, and at the first silent ischaemic event, triggered by the real-time ECG monitor, by means of an ambulatory blood withdrawal pump. Metoprolol lowered blood pressure and heart rate in both normotensive and hypertensive subjects, and reduced the frequency and duration of silent ischaemic episodes in hypertensive subjects. Plasma noradrenaline measured during silent ischaemia while the patients were resting was significantly higher than the control supine level without ischaemia. These findings suggest that noradrenergic hyperactivity may have a role in coronary vasoconstriction and that treatment which neutralizes sympathetic tone may be especially beneficial in treatment of silent ischaemia in hypertensive patients.
Lee
D D
DD
University of Southern California School of Medicine, Los Angeles.
Kimura
S
S
DeQuattro
V
V
D000787:Angina Pectoris / Q000097:blood / Q000150:complications; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D004562:Electrocardiography; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009638:Norepinephrine / Q000097:blood*; D009647:Normetanephrine / Q000097:blood*; D011379:Prognosis; D011897:Random Allocation; D013997:Time Factors
D009647:Normetanephrine; D008790:Metoprolol; D009638:Norepinephrine; D004837:Epinephrine